BioCardia (BCDA) Stock Price, News & Analysis

Company Overview

BioCardia, Inc. is a biotechnology company focused on developing regenerative cell therapies and delivery systems for the treatment of cardiovascular diseases. The company’s programs are designed to address conditions in which damaged or poorly functioning heart tissue may benefit from cellular therapy.

BioCardia’s principal product candidates include CardiAMP Cell Therapy, an autologous treatment that uses a patient’s own bone marrow-derived cells, and CardiALLO Cell Therapy, an investigational allogeneic therapy based on mesenchymal precursor cells from a donor source. The company also develops specialized catheter-based systems intended to deliver cell therapies to targeted areas of the heart.

Founded in 2002 and headquartered in Sunnyvale, California, BioCardia conducts clinical development activities in the United States and has worked with research and clinical partners internationally. The company is led by Peter Altman, Ph.D., who serves as president and chief executive officer.

Key Stats

• Today's Range: $0.85 to $0.93
• 50-Day Range: $0.85 to $1.25
• 52-Week Range: $0.75 to $1.80
• Volume: 167,664 shs
• Average Volume: 116,829 shs
• Market Capitalization: $12.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.00
• Consensus Rating: Hold

BioCardia Stock Analysis - MarketRank™

BioCardia scored higher than 48% of companies evaluated by MarketBeat, and ranked 535th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

BioCardia has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

BioCardia has a consensus price target of $25.00, representing about 2,841.2% upside from its current price of $0.85.

Amount of Analyst Coverage

BioCardia has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioCardia are expected to grow in the coming year, from ($0.71) to ($0.58) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioCardia is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioCardia is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioCardia has a P/B Ratio of 10.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.43% of the float of BioCardia has been sold short.

Short Interest Ratio / Days to Cover

BioCardia has a short interest ratio ("days to cover") of 5.05.

Change versus previous month

Short interest in BioCardia has recently increased by 9.57%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioCardia does not currently pay a dividend.

Dividend Growth

BioCardia does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 4 news articles for BioCardia this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for BCDA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

1 people have added BioCardia to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.7 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $11,142.00 in company stock, which represents 0.0866% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, BioCardia insiders have bought more of their company's stock than they have sold. Specifically, they have bought $11,142.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

17.40% of the stock of BioCardia is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

20.57% of the stock of BioCardia is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 11/08/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BCDA
• CIK: 925741
• Web: www.biocardia.com
• Phone: (650) 226-0123
• Fax: 310-861-5299
• Employees: 21
• Year Founded: 2002

Price Target and Rating

• Average Price Target for BioCardia: $25.00
• High Price Target: $25.00
• Low Price Target: $25.00
• Potential Upside/Downside: +2,841.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.23 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -569.36%
• Return on Assets: -183.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.09
• Quick Ratio: 2.09

Sales & Book Value

• Annual Sales: $60 thousand
• Price / Sales: 214.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.08 per share
• Price / Book: 10.63

Miscellaneous

• Outstanding Shares: 15,140,000
• Free Float: 12,505,000
• Market Cap: $12.87 million
• Optionable: Optionable
• Beta: 0.69